ZyVersa's Q3 Loss Soars on $18.6M R&D Impairment, Cash Dwindles

TL;DR

**ZVSA is burning cash and impaired its core R&D, making it a highly speculative bet with significant going concern risk.**

AI Summary

ZyVersa Therapeutics, Inc. reported a significant net loss of $19,805,559 for the three months ended September 30, 2025, a substantial increase from the $2,401,256 loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $24,273,806, compared to $7,991,736 in the prior year. This dramatic increase in loss was primarily driven by an impairment of in-process research and development totaling $18,647,903 during the nine-month period. The company's cash position decreased significantly, from $1,530,924 at December 31, 2024, to $527,978 as of September 30, 2025. Total assets plummeted from $20,599,414 to $1,040,260, largely due to the impairment charge. ZyVersa also reported a working capital deficit of approximately $11.8 million and an accumulated deficit of $136.9 million as of September 30, 2025, raising substantial doubt about its ability to continue as a going concern. Despite these challenges, the company engaged in financing activities, raising $3,697,746 in net cash from financing for the nine months ended September 30, 2025, primarily through private placements and warrant exercises.

Why It Matters

This filing paints a grim picture for ZyVersa Therapeutics, highlighting severe financial distress that could impact investors, employees, and future drug development. The substantial $18.6 million impairment of in-process R&D signals a potential setback in their drug pipeline, which is critical for a clinical-stage biopharmaceutical company. For investors, the 'going concern' warning and dwindling cash reserves mean a high risk of further dilution or even bankruptcy. Employees face job insecurity, and customers (future patients) may see delays or abandonment of promising therapies if the company cannot secure additional funding. In a competitive biopharma landscape, ZyVersa's inability to sustain operations could lead to its intellectual property being acquired or its projects stalled indefinitely.

Risk Assessment

Risk Level: high — ZyVersa Therapeutics faces a high risk level due to a 'going concern' warning, a net loss of $24.3 million for the nine months ended September 30, 2025, and a cash balance of only $527,978. The company also reported an accumulated deficit of $136.9 million and a working capital deficit of $11.8 million, indicating severe liquidity issues and an inability to cover short-term obligations.

Analyst Insight

Investors should exercise extreme caution and consider divesting any holdings in ZVSA. The 'going concern' warning, massive accumulated deficit, and significant cash burn suggest a high probability of further dilution or potential bankruptcy. New investors should avoid ZVSA until the company demonstrates a clear path to sustainable funding and successful clinical development.

Financial Highlights

total Assets

$1,040,260

net Income

-$24,273,806

cash Position

$527,978

Key Numbers

• $24.3M — Net Loss (for the nine months ended September 30, 2025, significantly higher than $7.99M in 2024)
• $18.6M — Impairment of In-Process R&D (major non-cash charge contributing to the net loss)
• $0.5M — Cash Balance (as of September 30, 2025, down from $1.53M at year-end 2024)
• $11.8M — Working Capital Deficit (as of September 30, 2025, indicating severe liquidity issues)
• $136.9M — Accumulated Deficit (as of September 30, 2025, reflecting historical losses)
• $4.7M — Cash Used in Operations (for the nine months ended September 30, 2025)
• 8,095,921 — Shares Outstanding (as of November 17, 2025, up from 2,508,191 at December 31, 2024, indicating dilution)
• $3.7M — Net Cash from Financing (for the nine months ended September 30, 2025, primarily from warrant exercises and private placements)

Key Players & Entities

• ZyVersa Therapeutics, Inc. (company) — clinical stage biopharmaceutical company
• $19,805,559 (dollar_amount) — net loss for three months ended September 30, 2025
• $2,401,256 (dollar_amount) — net loss for three months ended September 30, 2024
• $24,273,806 (dollar_amount) — net loss for nine months ended September 30, 2025
• $7,991,736 (dollar_amount) — net loss for nine months ended September 30, 2024
• $18,647,903 (dollar_amount) — impairment of in-process research and development
• $527,978 (dollar_amount) — cash as of September 30, 2025
• $1,530,924 (dollar_amount) — cash as of December 31, 2024
• $11.8 million (dollar_amount) — working capital deficit as of September 30, 2025
• $136.9 million (dollar_amount) — accumulated deficit as of September 30, 2025

FAQ

Risk Factors

• Substantial Net Losses and Going Concern Uncertainty [high — financial]: ZyVersa reported a net loss of $19,805,559 for the three months ended September 30, 2025, a significant increase from $2,401,256 in the prior year. The nine-month net loss was $24,273,806, up from $7,991,736. This, coupled with a cash balance of $527,978 and a working capital deficit of $11.8 million, raises substantial doubt about the company's ability to continue as a going concern.
• Significant Impairment of R&D Assets [high — financial]: An impairment of in-process research and development totaling $18,647,903 was recognized during the nine months ended September 30, 2025. This non-cash charge substantially contributed to the increased net loss and the drastic reduction in total assets from $20,599,414 to $1,040,260.
• Deteriorating Cash Position and Liquidity [high — financial]: The company's cash balance has fallen to $527,978 as of September 30, 2025, a sharp decline from $1,530,924 at December 31, 2024. Operating activities consumed $4.7 million in cash for the nine months ended September 30, 2025, exacerbating liquidity concerns.
• Shareholder Dilution [medium — financial]: The number of outstanding shares increased significantly from 2,508,191 at December 31, 2024, to 8,095,921 as of November 17, 2025. This substantial dilution is a result of financing activities, including private placements and warrant exercises, which raised $3,697,746 in net cash.
• Dependence on Future Financing [high — operational]: Given the significant operating losses and negative cash flow, ZyVersa is heavily reliant on continued access to capital markets. Failure to secure additional funding could impede its ability to fund ongoing operations and research and development activities.

Industry Context

The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like ZyVersa often rely on substantial external funding to advance their pipelines. The competitive landscape is intense, with many companies vying for funding and market share, making successful commercialization critical.

Regulatory Implications

As a biotechnology company, ZyVersa is subject to stringent regulations from bodies like the FDA. Delays in clinical trials, failure to obtain regulatory approval for its drug candidates, or non-compliance with manufacturing standards can have severe financial and operational consequences. The current financial distress may also impact its ability to meet ongoing compliance requirements.

What Investors Should Do

1. Monitor future financing activities closely for signs of continued dilution or inability to raise capital.
2. Scrutinize the progress and viability of R&D projects, especially given the recent impairment charge.
3. Assess the company's ability to address the going concern warning through strategic operational changes or successful fundraising.
4. Evaluate the competitive landscape and the company's differentiation in its therapeutic areas.

Key Dates

• 2025-09-30: Quarterly Report (10-Q) filed — Provides updated financial performance and condition, highlighting significant losses and a going concern warning.
• 2025-12-31: Previous Fiscal Year End — Benchmark for comparison of current financial position, showing a higher cash balance and total assets.

Glossary

In-process research and development

Costs incurred for research and development activities that have not yet reached technological feasibility or have no alternative future use. These are often expensed immediately or impaired if their future economic benefit is deemed unlikely. (A significant impairment charge of $18,647,903 related to this category heavily impacted the company's net loss and asset values.)

Going concern

An accounting assumption that a business will continue to operate for the foreseeable future. If substantial doubt exists about a company's ability to continue as a going concern, it must be disclosed. (The company's financial condition, including its net losses and low cash balance, has led to substantial doubt about its ability to continue as a going concern.)

Working capital deficit

Occurs when a company's current liabilities exceed its current assets, indicating a potential short-term liquidity problem. (ZyVersa has a working capital deficit of approximately $11.8 million, signaling severe liquidity issues.)

Accumulated deficit

The cumulative net losses of a company since its inception that have not been offset by profits or additional paid-in capital. (The company has an accumulated deficit of $136.9 million, reflecting its history of net losses.)

Warrant exercises

The process by which holders of stock warrants purchase shares of the company's stock at a specified price, providing the company with capital. (Warrant exercises were a source of net cash from financing activities, contributing to the $3,697,746 raised.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, ZyVersa Therapeutics has experienced a dramatic increase in net losses, with the nine-month period ending September 30, 2025, showing a loss of $24.3 million versus $7.99 million in 2024. This widening loss is largely attributable to a significant $18.6 million impairment of in-process R&D. Consequently, total assets have plummeted, and the cash position has weakened considerably. New risks related to the going concern status and severe liquidity issues have emerged prominently.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ZVSA * Indica
• $18.6 million — red. Therefore, the Company recorded an $18.6 million impairment charge, reflected within ope

Filing Documents

• form10-q.htm (10-Q) — 1052KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 19KB
• ex32-1.htm (EX-32.1) — 10KB
• 0001493152-25-024263.txt ( ) — 4932KB
• zvsa-20250930.xsd (EX-101.SCH) — 40KB
• zvsa-20250930_cal.xml (EX-101.CAL) — 39KB
• zvsa-20250930_def.xml (EX-101.DEF) — 142KB
• zvsa-20250930_lab.xml (EX-101.LAB) — 369KB
• zvsa-20250930_pre.xml (EX-101.PRE) — 263KB
• form10-q_htm.xml (XML) — 745KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 1

Financial Statements

Item 1. Financial Statements. 1 Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 1 Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 2 Unaudited Condensed Consolidated Statements of Changes in Stockholders' (Deficit) Equity for the Three and Nine Months Ended September 30, 2025 and 2024 3 Unaudited Condensed Consolidated Statements of Cash Flows for the Three and Nine Months Ended September 30, 2025 and 2024 5 Notes to Unaudited Condensed Consolidated Financial Statements 6

Management's Discussion and Analysis of Financial Condition and Results of Operations

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. 13

Quantitative and Qualitative Disclosures About Market Risk

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk. 19

Controls and Procedures

ITEM 4. Controls and Procedures. 19

- OTHER INFORMATION

PART II - OTHER INFORMATION 20

Legal Proceedings

ITEM 1. Legal Proceedings. 20

Risk Factors

ITEM 1A. Risk Factors . 20

Unregistered Sales of Equity Securities and Use of Proceeds

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds. 20

Defaults Upon Senior Securities

ITEM 3. Defaults Upon Senior Securities . 20

Mine Safety Disclosures

ITEM 4. Mine Safety Disclosures. 20

Other Information

ITEM 5. Other Information . 20 ITEM 6. Exhibits. 21

SIGNATURES

SIGNATURES 22 ZYVERSA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, December 31, 2025 2024 (Unaudited) Assets Current Assets: Cash $ 527,978 $ 1,530,924 Prepaid expenses and other current assets 298,192 184,873 Vendor deposits 169,363 - Total Current Assets 995,533 1,715,797 In-process research and development - 18,647,903 Vendor deposits - 178,476 Deferred offering costs 44,727 57,238 Total Assets $ 1,040,260 $ 20,599,414 Liabilities and Stockholders' (Deficit) Equity Current Liabilities: Accounts payable $ 9,805,129 $ 9,337,267 Accrued expenses and other current liabilities 2,960,698 1,894,041 Total Current Liabilities 12,765,827 11,231,308 Deferred tax liability - 851,659 Total Liabilities 12,765,827 12,082,967 Commitments and contingencies (Note 7) - - Stockholders' (Deficit) Equity: Preferred stock, $ 0.0001 par value, 1,000,000 shares authorized: Series A preferred stock, 8,635 shares designated, 50 shares issued and outstanding as of September 30, 2025 and December 31, 2024 - - Series B preferred stock, 5,062 shares designated, 5,062 shares issued and outstanding as of September 30, 2025 and December 31, 2024 1 1 Preferred stock 1 1 Common stock, $ 0.0001 par value, 250,000,000 shares authorized; 8,095,928 and 2,508,198 shares issued as of September 30, 2025 and December 31, 2024, respectively, and 8,095,921 and 2,508,191 shares outstanding as of September 30, 2025 and December 31, 2024, respectively 809 251 Common stock 809 251 Additional paid-in-capital 125,187,156 121,155,922 Accumulated deficit ( 136,906,365 ) ( 112,632,559 ) Treasury stock, at cost, 7 shares at September 30, 2025 and December 31, 2024 ( 7,168 ) ( 7,168 ) Total Stockholders' (Deficit) Equity ( 11,725,567 ) 8,516,447 Total Liabilities and Stockholders' (Deficit) Equity $ 1,040,260 $ 20,599,414 The accompanying notes are an integra

View Full Filing

View this 10-Q filing on SEC EDGAR